Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

Specimen Handling 36Magnetic Resonance Spectroscopy 31Cyclophosphamide 26Doxorubicin 23Biopsy 22pembrolizumab 21Temozolomide 21X-Rays 17Radiotherapy 17Radiation 16Nivolumab 13atezolizumab 12Vincristine 12Phantoms, Imaging 12Irinotecan 12Ifosfamide 12Gemcitabine 12fludarabine 11cabozantinib 10liposomal doxorubicin 8Surgical Procedures, Operative 8Ipilimumab 8Etoposide 8Bevacizumab 8Paclitaxel 7Immunoglobulin G 7Carboplatin 7palbociclib 6olaparib 6fludarabine phosphate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liquid Biopsy × Sarcoma × 90 days × Clear all
NCT06068075 2026-05-05

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Dana-Farber Cancer Institute

Phase NA Active not recruiting
340 enrolled
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡